Country/Language
Atherosclerotic cardiovascular disease (ASCVD) is an umbrella term for the clinical manifestations of fatty plaque build-up within the walls of arteries. It refers to diseases including coronary heart disease, cerebrovascular diseases, peripheral artery disease and more. Plaque build-up causes narrowed or blocked blood vessels, which restricts or completely obstructs blood flow, leading to serious cardiovascular events like a heart attack or stroke.
Despite advances in treatment, cardiovascular disease (CVD) is still the leading cause of death globally, resulting in over 17 million deaths annually. Elevated levels of bad cholesterol also known as low-density lipoprotein cholesterol (LDL-C) is a very important risk factor for the development of CVD.
Patients with documented ASCVD are at very high risk to experience future serious cardiovascular events, and many patients with ASCVD are unable to reduce their high levels of LDL-C cholesterol sufficiently to reach a desired (target) level. The study drug obicetrapib may offer a potentially effective option for these people to reach this desired LDL-C level.